CA2508871C - Forme cristalline f de sel d'hemi-calcium d'astorvastatine - Google Patents

Forme cristalline f de sel d'hemi-calcium d'astorvastatine Download PDF

Info

Publication number
CA2508871C
CA2508871C CA002508871A CA2508871A CA2508871C CA 2508871 C CA2508871 C CA 2508871C CA 002508871 A CA002508871 A CA 002508871A CA 2508871 A CA2508871 A CA 2508871A CA 2508871 C CA2508871 C CA 2508871C
Authority
CA
Canada
Prior art keywords
crystalline form
ketone
process according
preparation
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002508871A
Other languages
English (en)
Other versions
CA2508871A1 (fr
Inventor
Fritz Blatter
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02406037A external-priority patent/EP1424324A1/fr
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2508871A1 publication Critical patent/CA2508871A1/fr
Application granted granted Critical
Publication of CA2508871C publication Critical patent/CA2508871C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne la forme polymorphe F de calcium d'atorvastatine, des procédés de sa préparation et de compositions pharmaceutiques comportant cette forme cristalline.
CA002508871A 2002-11-28 2003-11-26 Forme cristalline f de sel d'hemi-calcium d'astorvastatine Expired - Fee Related CA2508871C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02406037A EP1424324A1 (fr) 2002-11-28 2002-11-28 Forme cristalline F de calcium d'atorvastatine
EP02406037.8 2002-11-28
EP03405110.2 2003-02-20
EP03405110 2003-02-20
PCT/US2003/038090 WO2004050618A2 (fr) 2002-11-28 2003-11-26 Forme cristalline

Publications (2)

Publication Number Publication Date
CA2508871A1 CA2508871A1 (fr) 2004-06-17
CA2508871C true CA2508871C (fr) 2008-09-09

Family

ID=32471910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508871A Expired - Fee Related CA2508871C (fr) 2002-11-28 2003-11-26 Forme cristalline f de sel d'hemi-calcium d'astorvastatine

Country Status (4)

Country Link
EP (1) EP1572643A2 (fr)
AU (1) AU2003297594A1 (fr)
CA (1) CA2508871C (fr)
WO (1) WO2004050618A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406436C (zh) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
CA2573771C (fr) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Nouvelles formes de sel de calcium (2:1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
ES2262459T1 (es) * 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
CA2579997A1 (fr) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Procede de preparation de formes d'atorvastatine calcique sensiblement exemptes d'impuretes
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20090018182A1 (en) * 2006-06-28 2009-01-15 Sigalit Levi Crystalline forms of atorvastatin
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
WO2009007856A2 (fr) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
PT1535613E (pt) * 1999-11-17 2010-10-04 Teva Pharma Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
ES2258030T3 (es) * 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
JP2003517038A (ja) * 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチン三水和物半カルシウム塩の工場規模での製造方法
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL365312A1 (en) * 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
KR100609371B1 (ko) * 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
PL368647A1 (en) * 2001-07-30 2005-04-04 Dr.Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
CN100406436C (zh) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CA2491051A1 (fr) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Forme vi de calcium d'atorvastatine ou hydrates de cette derniere

Also Published As

Publication number Publication date
AU2003297594A8 (en) 2004-06-23
WO2004050618A3 (fr) 2004-07-15
EP1572643A2 (fr) 2005-09-14
WO2004050618A2 (fr) 2004-06-17
WO2004050618A8 (fr) 2005-07-14
AU2003297594A1 (en) 2004-06-23
CA2508871A1 (fr) 2004-06-17

Similar Documents

Publication Publication Date Title
CA2508871C (fr) Forme cristalline f de sel d'hemi-calcium d'astorvastatine
US7189861B2 (en) Processes for preparing amorphous atorvastatin hemi-calcium
KR100400805B1 (ko) 무정형[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산칼슘염(2:1)의신규제조방법
CA2431068C (fr) Formes cristallines d'atorvastatine
CZ20021642A3 (cs) Polymorfní formy atorvastatinu vápenatého
AU2010340799A1 (en) Darunavir polymorph and process for preparation thereof
US20080269315A1 (en) Crystalline form
EP1465901A2 (fr) Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
CA2672554C (fr) Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
EP3471734B1 (fr) Formes à l'état solide de citrate d'ixazomib
JP2009500429A (ja) 保存後も安定なアトルバスタチンカルシウムの結晶形
HU227124B1 (en) Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
WO2012015157A1 (fr) Nouvelle forme cristalline du sel d'hémicalcium de l'atorvastatine, son hydrate et son procédé de production
MX2008000375A (en) Crystalline form of atorvastatin calcium stable after storage
AU2007205725A1 (en) Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2009139730A1 (fr) Fabrication de nouvelles formes non cristallines d'atorvastatine calcique
ZA200303976B (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed